Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 34 EP applications Christopher Spencer Winter has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 15, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13182099

Engineered Fc regions for site-specific conjugation

IPC classification:
A61K 39/00, A61K 47/48, C07K 16/00, C12P 21/08
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11841807

COMBINATION THERAPY FOR B CELL LYMPHOMAS

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/28
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13168817

Methods of treating systemic lupus erythematosus

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12196199

Antibodies with decreased deamidation profiles

IPC classification:
A61K 9/00, A61K 39/395, A61K 47/02, A61K 47/12, A61K 47/18, A61K 47/26, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12756712

ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Cambridge Enterprise Ltd.
Applicant:
MedImmune Limited
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP12848121

MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF

IPC classification:
A61K 39/00
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP14169713

Optimized degenerative muscle disease diagnostics and treatments

IPC classification:
A61K 31/56, A61K 31/7088, A61K 35/34, A61K 39/00, A61K 39/395, A61K 45/00, C12Q 1/00, C12Q 1/68, G01N 33/48, G01N 33/53, G01N 33/68
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13758582

METHODS OF TREATMENT WITH ANGIOPOIETIN-2 ANTIBODIES

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/00
Applicant:
MedImmune, LLC
Applicant:
University of Helsinki (Helsingin yliopisto)
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP13784604

MOLECULES WITH REDUCED EFFECTOR FUNCTION AND EXTENDED HALF-LIVES, COMPOSITIONS, AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/00, C12P 21/08
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP13803921

FIXED DOSAGE REGIMENS FOR ANTI-TYPE I INTERFERON RECEPTOR (IFNAR) ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP11769481

TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS

IPC classification:
A61K 39/00, A61K 39/395, C07K 14/00, C07K 14/78, C07K 16/10, C07K 16/28, C07K 16/46, C07K 19/00
Applicant:
MedImmune, LLC
Agent:
AstraZeneca PLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP13805277

ANTIBODIES TO AMYLOID BETA

IPC classification:
C07K 16/18
Applicant:
MedImmune Limited
Agent:
Diana Jean Pisani, Ropes & Gray International LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Agent:
Jeremy Suhail Rashid, White & Case LLP
Status:
EXAMINATION IN PROGRESS
EP14186905

Anti-ILT7 antibody

IPC classification:
A61K 39/00, A61K 39/395, A61P 37/00, C07K 16/28, G01N 33/566, G01N 33/577, G01N 33/68
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP12168586

Anti-ILT7 antibody

IPC classification:
A61K 39/00, A61K 39/395, A61K 48/00, A61P 17/06, A61P 31/18, A61P 35/00, A61P 37/02, A61P 43/00, C07K 16/28, C12N 5/10, C12P 21/08, G01N 33/53, G01N 33/566, G01N 33/577, G01N 33/68
Agent:
Multiple attorneys, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13853844

METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES

IPC classification:
A61K 39/085
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11755347

CHINESE HAMSTER OVARY CELL LINE

IPC classification:
C12N 5/16
Applicant:
MedImmune Limited
Agent:
Multiple attorneys, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14766962

ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP11761051

FACTOR II ALONE OR IN COMBIATION WITH FURTHER FACTORS FOR TREATMENT OF IMPAIRED HAEMOSTASIS ASSOCIATED WITH DILUTIONAL COAGULOPATHY

IPC classification:
A61K 38/36, A61K 38/48, A61P 7/04
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
PATENT GRANTED
EP14850550

NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF

IPC classification:
A61P 31/16
Applicant:
MedImmune, LLC
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11741602

MONOMERIC POLYPEPTIDES COMPRISING VARIANT FC REGIONS AND METHODS OF USE

IPC classification:
C07K 16/28
Applicant:
MedImmune Limited
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11817285

DETECTION OF LCAT ACTIVITY

IPC classification:
C12Q 1/48
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11858565

HSA-RELATED COMPOSITIONS AND METHODS OF USE

IPC classification:
A61K 38/38, A61K 47/48, C07K 14/765
Applicant:
MedImmune, LLC
Agent:
Thomas Zvesper, Mathys & Squire LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14856296

ANTIBODY PURIFICATION

IPC classification:
B01D 15/08, C07K 16/00, C07K 16/18
Applicant:
MedImmune, LLC
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15769523

SINGLE-USE, SELF DESTRUCTING SHIELD FOR SYRINGE NEEDLE

IPC classification:
A61M 5/32
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15777039

CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES

IPC classification:
C07K 16/30
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15777523

TUBULYSIN DERIVATIVES

IPC classification:
A61K 31/426, A61K 31/427, C07D 277/30
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15788683

METHODS OF USING ANTI-ANG2 ANTIBODIES

IPC classification:
A61K 39/395
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15722195

ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15727571

TREATMENT FOR RHEUMATOID ARTHRITIS

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/28
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15726122

ANTAGONISTS OF PDL-1 AND PD-1 FOR THE TREATMENT OF HPV-NEGATIVE CANCERS

IPC classification:
A61K 39/00, C07K 16/28, C07K 16/30
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP16199226

COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15763528

METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY USING MARKERS (CXCL9, KRT8.TRIM29, AND IFNGAMMA)

IPC classification:
A61K 39/00, A61P 35/00, C07K 14/47, C07K 14/52, C07K 16/28, C12Q 1/68, G01N 33/574
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made
EP15782151

METHOD OF CONJUGATING A POLYPEPTIDE

IPC classification:
A61K 47/50
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made
EP15848683

HUMANIZED ANTI-OX40 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/28
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made

Please Sign in to use this feature